Radiosensitizing effect of a novel CTSS inhibitor by enhancing BRCA1 protein stability in triple‐negative breast cancer cells
Cancer Science · 2024
DOI: 10.1111/cas.16174 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Science, 2024. Verfasst von Eun Choi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Graduate School of Pharmaceutical Sciences and College of Pharmacy, Ewha Women's University, Seoul, Korea. Hauptthemen laut MEDLINE: Apoptosis, BRCA1 Protein, Radiation-Sensitizing Agents, Triple Negative Breast Neoplasms. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Ministry of Science and ICT, South Korea.
Abstract (Originalsprache)
Triple‐negative breast cancer (TNBC) patients harboring wild‐type breast cancer susceptibility gene 1 (BRCA1) account for most TNBC patients but lack adequate targeted therapeutic options. Although radiotherapy (RT) is the primary treatment modality for TNBC patients, radioresistance is one of the major challenges. RT‐induced increase in cathepsin S (CTSS) causes radioresistance through suppressing BRCA1‐mediated apoptosis of tumor cells, which was induced by CTSS‐mediated degradation of BRCA1. Targeting CTSS may provide a novel therapeutic opportunity for TNBC patients. Publicly available data and human tissue microarray slides were analyzed to investigate the relationship between CTSS and BRCA1 in breast cancer patients. A CTSS enzyme assay and in silico docking analysis were conducted to identify a novel CTSS inhibitor. RO5461111 was used first to confirm the concept of targeting CTSS for radiosensitizing effects. The MDA‐MB‐231 TNBC cell line was used for in vitro and in vivo assays. Western blotting, promoter assay, cell death assay, clonogenic survival assay, and immunohistochemistry staining were conducted to evaluate novel CTSS inhibitors. CTSS inhibitors were further evaluated for their additional benefit of inhibiting cell migration. A novel CTSS inhibitor, TS‐24, increased BRCA1 protein levels and showed radiosensitization in TNBC cells with wild‐type BRCA1 and in vivo in a TNBC xenograft mouse model. These effects were attributed by BRCA1‐mediated apoptosis facilitated by TS‐24. Furthermore, TS‐24 demonstrated the additional effect of inhibiting cell migration. Our study suggests that employing CTSS inhibitors for the functional restoration of BRCA1 to enhance RT‐induced apoptosis may provide a novel therapeutic opportunity for TNBC patients harboring wild‐type BRCA1.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Graduate School of Pharmaceutical Sciences and College of Pharmacy, Ewha Women's University, Seoul, Korea.
- College of Pharmacy, CHA University, Pocheon, Korea.
ORCID-Profile: Yun-Sil Lee
Förderung
- Ministry of Science and ICT, South Korea
Zitieren
APA
Choi, E., Jeon, K. H., Lee, H., Mun, G. I., Kim, J. A., Shin, J. H., Kwon, Y., Na, Y., & Lee, Y. S. (2024). Radiosensitizing effect of a novel CTSS inhibitor by enhancing BRCA1 protein stability in triple‐negative breast cancer cells. Cancer Science. https://doi.org/10.1111/cas.16174
Vancouver
Choi E, Jeon KH, Lee H, Mun GI, Kim JA, Shin JH, et al. Radiosensitizing effect of a novel CTSS inhibitor by enhancing BRCA1 protein stability in triple‐negative breast cancer cells. Cancer Science. 2024. doi:10.1111/cas.16174
BibTeX
@article{Choi2024,
author = {Choi, Eun and Jeon, Kyung-Hwa and Lee, Hanhee and Mun, Gil-Im and Kim, Jeong-Ahn and Shin, Jae-Ho and Kwon, Youngjoo and Na, Younghwa and Lee, Yun-Sil},
title = {Radiosensitizing effect of a novel CTSS inhibitor by enhancing BRCA1 protein stability in triple‐negative breast cancer cells},
journal = {Cancer Science},
year = {2024},
doi = {10.1111/cas.16174}
}
EUVIMED